BPS is an autonomous division of the American Pharmacists Association. To maintain its strict, independent standards for certification, BPS does NOT endorse or provide review information, preparatory courses, or study guides for board certification examinations. BPS, through its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects of its certification programs. BPS is totally separate and distinct from ACCP. For information about BPS specialty recertification the BPS recertification process, go to: www.bpsweb.org/
To receive recertification credit, posttests must be submitted prior to the recertification posttest deadline (see above). Only completed tests are eligible for credit; no partial or incomplete tests will be processed. You may complete one or all available posttests for credit.
The passing point to earn recertification credit is based on an expert analysis of the assessment items in each posttest. Any posttest submitted before the recertification test deadline that meets this passing point will earn recertification credits. These credits will be assigned as of the date of test submission and reported within 48 hours to BPS. For statements of recertification credit, visit www.bpsweb.org.
In accordance with BPS guidelines concerning remediation for products launched in 2024 and after, posttests that do not reach the passing point for recertification credit will generate a second-chance test option. This test will automatically appear in the learner’s My Account page and will have assessment items presented in a different order. To qualify for recertification credit, the second-chance test must be submitted before the recertification deadline stated above.
Antimicrobial Stewardship; Upper Respiratory Tract Infections; Lower Respiratory Tract InfectionsActivity Number: 0204-9999-26-925-H01-P
Contact Hour(s): 5.50
Activity Type: Application BasedLearning Objectives
Antimicrobial Stewardship
- Outline components of an effective stewardship program.
- Select appropriate resources; relevant accreditation, legal, regulatory, and safety requirements; and quality metrics related to infectious diseases.
- Evaluate institutional treatment policies and pathways for compliance with antimicrobial stewardship guidelines, surveillance data, and best available evidence.
- Assess the effectiveness of infection prevention strategies.
- Identify metrics for evaluating the value of infectious diseases pharmacy services.
Upper Respiratory Tract Infections
- Assess pharmacotherapies for upper respiratory tract infections.
- Select the most appropriate pharmacotherapeutic plan and monitoring based on patient- and disease-specific information, antibiogram data, and best available evidence.
- Recommend modifications of patient-specific treatment plans based on efficacy and adverse effects.
- Identify recommended immunizations and potential adverse effects.
Lower Respiratory Tract Infections
- Assess pharmacotherapies for lower respiratory tract infections, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics.
- Assess the advantages and disadvantages of pharmacotherapies for viral pneumonia, including recommendations for specific patient populations.
- Select the most appropriate pharmacotherapeutic plan and monitoring based on patient- and disease-specific information, antibiogram data, and best available evidence.
- List recommended immunizations and screening guidelines for patients with or at risk for COVID-19, influenza, and respiratory syncytial virus.
- Interpret signs, symptoms, and laboratory and other relevant diagnostic test results.
- Recommend the most appropriate modifications of patient-specific treatment plans based on efficacy, adverse effects, and follow-up assessment.
- Interpret biomedical literature with regard to study design and methodology, significance of reported data and conclusions, limitations, and applicability of study results to patients with lower respiratory tract infections.
|
HIV/AIDS; Infections of Reproductive Organs and Sexually Transmitted Infections; Opportunistic Infections in Immunocompromised PatientsActivity Number: 0204-9999-26-926-H01-P
Contact Hour(s): 5.00
Activity Type: Application BasedLearning Objectives
- Assess pharmacotherapies for HIV‐infection and AIDS, including opportunistic infections.
- Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence.
- List recommended immunizations and screening guidelines for patients with HIV.
- Recommend modifications of patient‐specific treatment plans based on efficacy, drug interactions, immunologic or virologic response, and adverse effects.
- Interpret signs, symptoms, and laboratory and other relevant diagnostic test results related to HIV infection.
- Evaluate a plan to facilitate transitions of care.
Infections of Reproductive Organs and Sexually Transmitted Infections
- Assess pharmacotherapies for infections of reproductive organs and sexually transmitted diseases.
- Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence.
- Identify recommended screening guidelines for sexually‐transmitted diseases.
- Recommend modifications of patient‐specific treatment plans based on efficacy, immunologic response, and adverse effects.
- Interpret signs, symptoms, and laboratory and other relevant diagnostic test results.
- Summarize key considerations in effective patient and caregiver education and counseling techniques.
Opportunistic Infections in Immunocompromised Patients
- Assess the advantages and disadvantages of pharmacotherapies for opportunistic infections in immunocompromised patients, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics.
- Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information and best available evidence.
- Interpret signs, symptoms, and laboratory and other relevant diagnostic test results.
- Recommend modifications of patient‐specific treatment plans based on efficacy, immunologic response, and adverse effects.
- Identify preventative therapies in immunocompromised patients.
|
Fungal Infections; Viral Hepatitis; Tuberculosis and Other Mycobacterial InfectionsActivity Number: 0204-9999-26-927-H01-P
Contact Hour(s): 5.50
Activity Type: Application BasedLearning ObjectivesFungal Infections
- Assess pharmacotherapies for invasive fungal infections including aspergillosis, candidiasis, dimorphic fungi, and cryptococcosis.
- Select the most appropriate pharmacotherapeutic plan and monitoring based on patient- and disease-specific information and best available evidence.
- Recommend modifications of patient-specific treatment plans based on efficacy, immunologic response, and adverse effects.
- Identify potential adverse effects and drug-drug interactions.
Viral Hepatitis
- Assess pharmacotherapies for viral hepatitis, including relevant pharmacology and spectrum of activity.
- Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, virus and genotype, and best available evidence.
- Interpret signs, symptoms, laboratory and other relevant diagnostic test results.
- Recommend modifications of patient‐specific treatment plans based on efficacy, adverse effects, and drug interactions.
- Summarize key considerations in effective patient and caregiver education and counseling techniques.
- Identify screening guidelines and preventive therapies for viral hepatitis.
Tuberculosis and Other Mycobacterial Infections
- Select the most appropriate pharmacotherapeutic plan and monitoring based on patient- and disease-specific information, antibiogram data, and best available evidence.
- Interpret signs, symptoms, laboratory and other relevant diagnostic test results.
- Recommend modifications of patient-specific treatment plans based on efficacy, adverse effects, and drug interactions.
- Outline key considerations in effective patient and caregiver education and counseling techniques.
- Identify screening guidelines and preventive therapies for tuberculosis and other mycobacterial infections.
|
Cardiovascular Infections; Asymptomatic Bacteriuria and Urinary Tract Infections; StatisticsActivity Number: 0204-9999-26-928-H01-P
Contact Hour(s): 5.50
Activity Type: Application BasedLearning ObjectivesCardiovascular Infections
- Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence.
- Identify drug‐related problems associated with the therapeutic plan.
- Recommend appropriate modifications of patient‐specific pharmacotherapeutic plans based on efficacy and adverse effects.
- Interpret biomedical literature with regard to study design and methodology, significance of reported data and conclusions, limitations, and applicability of study results to patients with cardiovascular infections.
Asymptomatic Bacteriuria and Urinary Tract Infections
- Evaluate antibiotics used for urinary tract infections (UTIs), including spectrum of activity, pharmacokinetics, and pharmacodynamics.
- Select the most appropriate antibiotic, route, and duration of therapy based on patient- and disease-specific information, antibiogram or susceptibility data, and best available evidence.
- Interpret signs, symptoms and laboratory test results to diagnose and categorize UTIs.
- Identify National Healthcare Safety Network reporting requirements for catheter-associated UTIs.
Statistics, Evidence-based Medicine, and Research Design
- Given an excerpt from a study…Evaluate quality and appropriateness, with specific attention to study design, statistical analysis, internal/external validity, source of bias/confounders, and quality of conclusions and interpretation of graphs.
- Explain why a statistical test is appropriate or not appropriate, based on the sample distribution, data type, and study design.
- Interpret clinical and statistical significance for results from commonly used statistical tests.
- Explain the strengths and limitations of different types of measures of central tendency (mean, median, and mode) and data spread (standard deviation, standard error of the mean, range, and interquartile range).
- Evaluate odds ratio, risk/incidence rate, relative risk, number needed to treat, number needed to harm, and other risk estimates.
- Assess whether the study applies to a specified patient population.
|
Bone/Joint/Skin Infections; Central Nervous System Infections; Clinical MicrobiologyActivity Number: 0204-9999-26-929-H01-P
Contact Hour(s): 5.00
Activity Type: Application BasedLearning ObjectivesBone and Joint Infections and Skin and Soft Tissue Infections
- Assess the advantages and disadvantages of pharmacotherapies for bone and joint infections and skin and soft tissue infections, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics.
- Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence.
- Identify drug‐related problems associated with the therapeutic plan.
- Interpret signs, symptoms, and laboratory and other relevant diagnostic test results.
- Recommend modifications of patient‐specific pharmacotherapeutic plans based on efficacy and adverse effects.
- Describe the etiology, diagnosis, and treatment of acute bacterial osteomyelitis and septic arthritis in pediatric patients.
Central Nervous System Infections
- Assess pharmacotherapies for central nervous system infections, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics.
- Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence.
- Interpret signs, symptoms, and laboratory and other relevant diagnostic test results.
- Identify preventive therapies for central nervous system infections.
Clinical Microbiology
- Explain the mechanisms of antimicrobial resistance among various pathogens.
- Identify basic microbiology laboratory procedures.
- Interpret laboratory and other diagnostic test results relevant to the diagnosis, management, and monitoring of patients with infectious diseases.
- Evaluate biomedical literature with regard to study design and methodology specific to infectious diseases.
|
Gastrointestinal and Intra-abdominal InfectionsActivity Number: 0204-9999-26-930-H01-P
Contact Hour(s): 1.50
Activity Type: Application BasedLearning ObjectivesGastrointestinal and Intra-abdominal Infections
- Assess pharmacotherapies for gastrointestinal and intra‐abdominal infections, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics.
- Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence.
- Interpret signs, symptoms, and laboratory and other relevant diagnostic test results.
- Recommend modifications of patient‐specific treatment plans based on efficacy, immunologic response, and adverse effects.
|
The American College of Clinical Pharmacy does not solicit or accept external commercial/financial support for its continuing pharmacy education activities. No commercial/financial support has been solicited or accepted for this activity.